This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
by Deepanwita Sarkar Saha
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
NVONegative Net Change LLYPositive Net Change ALTPositive Net Change MDGLPositive Net Change
biotechs
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
by Deepanwita Sarkar Saha
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
NVONegative Net Change LLYPositive Net Change ALTPositive Net Change MDGLPositive Net Change
biotechs
SNY's Tzield Gets FDA Nod for Kids, Sarclisa SC BLA Faces Delay
by Zacks Equity Research
Sanofi wins FDA nod to expand Tzield's use to younger patients, while Sarclisa SC review faces delay with a new decision date set for July 2026.
SNYNegative Net Change MGNXNegative Net Change INDVNegative Net Change
biotechs
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
by Zacks Equity Research
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
JNJPositive Net Change TAKNegative Net Change SYREPositive Net Change
biotechs medical pharmaceuticals
RHHBY's Q1 Results Hit by Currency Headwinds, Sales Up 6% at CER
by Zacks Equity Research
Roche's Q1 beat masks currency drag as strong drug demand drives CER growth and offsets biosimilar hit to legacy portfolio.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
by Ahan Chakraborty
Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
by Ahan Chakraborty
Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
by Ahan Chakraborty
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Do Options Traders Know Something About Alkermes Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ALKS stock based on the movements in the options market lately.
ALKSPositive Net Change
biotechnology biotechs medical
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
by Zacks Equity Research
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
INONegative Net Change ADMANegative Net Change INBXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals